Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 14:16:933290.
doi: 10.3389/fnins.2022.933290. eCollection 2022.

Chinese Herbal Medicine for Functional Dyspepsia With Psychological Disorders: A Systematic Review and Meta-Analysis

Affiliations

Chinese Herbal Medicine for Functional Dyspepsia With Psychological Disorders: A Systematic Review and Meta-Analysis

Xiaoying Luo et al. Front Neurosci. .

Abstract

Background and aims: Functional dyspepsia (FD) is closely associated with gut-brain interaction disorder (DGBI), characterized by the interaction of gastrointestinal symptoms and central nervous system dysregulation. Chinese herbal medicine (CHM) has a good concurrent effect in the treatment of FD, especially for patients with concurrent psychological disorders. A meta-analysis was designed to evaluate the efficacy and safety of CHMs in the treatment of FD.

Methods: The PubMed, Embase, Cochrane Library, Web of Science, Chinese Biological Medical Database (CBM), Wanfang Data, China National Knowledge Infrastructure (CNKI), and China Science and Technology Journal Database (VIP) were searched to collect randomized controlled trials of FD treated with CHM. The retrieval time limit is from the establishment of the database till 11 April 2022. Two researchers independently searched databases, screened documents, extracted data, and evaluated the risk of bias of included studies. RevMan 5.4 software was used for meta-analysis.

Results: A total of 11 studies including 951 patients were included. The study was divided into two parts. The first part included 5 clinical trials, including 471 patients. The experimental group was treated only with CHM and the control group was only treated with placebo. The results of first part showed that the total effective rate of CHM in the treatment of FD was higher than that in the placebo group (84.5 vs. 49.4%) [relative risk (RR) = 1.76; 95% confidence interval (CI) (1.13, 2.75); P = 0.01]. In addition, CHM treatment could reduce the total symptom score [standardized mean difference (SMD) = -10.05; 95% CI (-13.50, -6.59); Z = 5.70; P < 0.0001] and depression score [SMD = -7.68; 95% CI (-14.43, -0.94); Z = 2.23; P = 0.03]. The second part included 6 clinical trials, including 480 patients. The experimental group was only treated with CHM and the control group was treated with prokinetic agents combined with flupentixol melitracen (deanxit). The results of second part showed that the total effective rate of CHM in the treatment of FD was higher than that of the control group (92.6 vs. 78.8%) [RR = 1.17; 95% CI (1.09, 1.26), P < 0.0001]. In addition, CHM treatment could reduce HAMA score [mean difference (MD) = -3.19; 95% CI (-3.79, -2.59); Z = 10.40; P < 0.00001], HAMD score [MD = -4.32; 95% CI (-6.04, -2.61); Z = 4.94; P < 0.00001], and gastric emptying rate [MD = 12.62; 95% CI (5.84, 19.40); Z = 3.65; P = 0.0003]. The results of the two parts of the meta-analysis showed no serious adverse reactions, and there was no significant difference in the adverse reactions between the experimental group and the control group [MD = 1.14; 95% CI (0.53, 2.42); Z = 0.33; P = 0.74]; [MD = 0.14; 95% CI (0.01, 2.67); Z = 1.30; P = 0.19].

Conclusion: The current evidence shows that CHM treatment has great potential and safety in alleviating the symptoms of FD and improving the psychological disorders of anxiety and depression in patients with FD. Limited by the quantity and quality of the included studies and other biases, the above conclusions need more high-quality studies to be verified.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier [CRD42022311129].

Keywords: Chinese herbal medicine; effectiveness; functional dyspepsia (FD); metaanalysis; psychological disorder.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Article screening process.
FIGURE 2
FIGURE 2
Assessment of the risk of bias of CHM vs. placebo.
FIGURE 3
FIGURE 3
Assessment of the risk of bias of CHM vs. western medicine group.
FIGURE 4
FIGURE 4
Meta-analysis of total effective rate of CHM vs. placebo.
FIGURE 5
FIGURE 5
Meta-analysis of total effective rate of CHM vs. western medicine group.
FIGURE 6
FIGURE 6
Meta-analysis of total symptom score of CHM and placebo.
FIGURE 7
FIGURE 7
Meta-analysis of depression score of CHM vs. placebo.
FIGURE 8
FIGURE 8
Meta-analysis of HAMD score of CHM vs. western medicine group.
FIGURE 9
FIGURE 9
Meta-analysis of HAMA score of CHM vs. western medicine group.
FIGURE 10
FIGURE 10
Meta-analysis of gastric emptying rate of CHM vs. western medicine group.
FIGURE 11
FIGURE 11
Meta-analysis of adverse reactions of CHM and placebo.
FIGURE 12
FIGURE 12
Meta-analysis of adverse reactions of CHM vs. western medicine group.

Similar articles

Cited by

References

    1. Chen G., Feng P., Wang S., Ding X., Xiong J., Wu J., et al. (2020). An Herbal Formulation of Jiawei Xiaoyao for the Treatment of Functional Dyspepsia: A Multicenter, Randomized, Placebo-Controlled, Clinical Trial. Clin. Transl. Gastroenterol. 11:e00241. 10.14309/ctg.0000000000000241 - DOI - PMC - PubMed
    1. Chen Y. L. (2016). The psychosomatics viewpoint of chronic gastrointestinal disease. Chin. J. Diagn. Electron. 4 168–172.
    1. Chu M. H. K., Wu I. X. Y., Ho R. S. T., Wong C. H. L., Zhang A. L., Zhang Y., et al. (2018). Chinese herbal medicine for functional dyspepsia: systematic review of systematic reviews. Therap. Adv. Gastroenterol. 11:1756284818785573. 10.1177/1756284818785573 - DOI - PMC - PubMed
    1. Dersimonian R., Laird N. (1986). Meta-analysis in clinical trials. Control. Clin. Trials 7 177–188. 10.1016/0197-2456(86)90046-2 - DOI - PubMed
    1. Drossman D. A. (2021). Worldwide prevalence and burden of functional gastrotestinal disorders,results of Rome Foundation global study. Gastroenterology 160 99–114.e3. 10.1053/j.gastro.2020.04.014 - DOI - PubMed

Publication types